OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	372
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	230
Regulation of the hippocampal translatome by Apoer2-ICD release	221
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	207
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	202
Tau interactome and RNA binding proteins in neurodegenerative diseases	194
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	181
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	169
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	169
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	168
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	154
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	151
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	142
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	140
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	139
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	134
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	132
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	123
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	100
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	100
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	98
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	91
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	90
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	89
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	87

The role of NURR1 in metabolic abnormalities of Parkinson’s disease	85
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	83
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	79
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	76
Combination therapy using GDNF and cell transplant in Parkinson’s disease	73
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	72
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	72
In Memoriam of Edward H. Koo, MD 1954–2025	72
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	71
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	71
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	71
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	70
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	68
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	67
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	65
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	64
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	62
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	60
Using mass spectrometry to validate mouse models of tauopathy	58
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	55
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	55
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	55
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	54
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	53
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	53
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	53
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	52
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	51
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	50
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	48
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	48
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	48
The endotoxin hypothesis of Alzheimer’s disease	48
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	47
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	47
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	47
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	44
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	44
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	43
VCP suppresses proteopathic seeding in neurons	43
Mechanisms of astrocyte aging in reactivity and disease	43
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	42
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	42
Sex specific molecular networks and key drivers of Alzheimer’s disease	42
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	41
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	40
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	39
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	39
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	38
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	38

Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	38
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	36
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	36
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	36
Neuropathology and molecular diagnosis of Synucleinopathies	36
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	35
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	35
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	35
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	35
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	34
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	34
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	34
The role of inflammasomes in vascular cognitive impairment	33
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	33
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	33
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	33
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	33
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	33
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	32
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	32
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities	32
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease	32
Blood platelet factor 4: the elixir of brain rejuvenation	31
Microglial ferroptotic stress causes non-cell autonomous neuronal death	31
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	31
Elevated nuclear TDP-43 induces constitutive exon skipping	31
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	31